We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Will Semiconductor and Biotech Drive EMCOR's Bookings?
Read MoreHide Full Article
Key Takeaways
EME reached record RPOs of $11.75B in Q1 2025, up 28% year over year, including $1B from Miller Electric.
The government acts like CHIPS and IRA are boosting semiconductor and biotech project demand for EMCOR.
EME stock surged 56.2% in three months, outpacing peers KBR and ACM, supported by favorable market trends.
EMCOR Group, Inc.’s (EME - Free Report) prospects are notably benefiting from several initiatives that the United States government has undertaken to foster public infrastructure. Initiatives like the CHIPS Act and the Inflation Reduction Act (IRA) are helping to fuel the demand across the semiconductor and biotech market segments, thus benefiting EMCOR in its wake.
As of March 31, 2025, EME reached a record value of $11.75 billion for remaining performance obligations (RPOs), including $1 billion of RPOs from Miller Electric. The value reflects 28% year-over-year growth. The company measures its to-be-realized revenues from received and incomplete contracts through remaining performance obligations or RPOs.
EME considers projects across semiconductors, biotech, life sciences and pharmaceuticals under the High-Tech Manufacturing market sector. During the first quarter of 2025, the company witnessed a setback in this sector’s RPOs, with continued progress across several multi-year semiconductor projects being one of the reasons behind it. However, from a long-term perspective, it is optimistic about increased spending in this market sector, especially across semiconductor, biotech and pharmaceuticals.
The market visibility for long-term prospects for semiconductor and biotech projects remains solid. It is because the market is currently focused on AI alternatives, technological revolution, and health and wellness. These trends, supported by several ongoing federal and state initiatives, are fueling the demand for such projects, thus boosting EMCOR’s booking visibility in the upcoming period. The company’s ability to grab onto these market opportunities and capitalize on them efficiently is boding well for its revenue visibility and margin trends.
EME Stock’s Price Performance vs Other Market Players
Shares of this Connecticut-based infrastructure service provider have gained 56.2% in the past three months, outperforming the Zacks Building Products - Heavy Construction industry, the broader Construction sector and the S&P 500 index. The detailed share price performance is shown in the chart below.
Image Source: Zacks Investment Research
Other renowned firms that share the market space with EME across semiconductors, biotech, life sciences and pharmaceuticals segments include KBR, Inc. (KBR - Free Report) and AECOM (ACM - Free Report) . Although the market trends are favoring these companies, they are falling behind in realizing benefits from the robust fundamentals compared with EMCOR. During the past three months, shares of KBR and AECOM have gained 3.1% and 32.6%, respectively.
EMCOR’s Valuation Trend
EMCOR stock is currently trading at a premium compared with the industry peers, with a forward 12-month price-to-earnings (P/E) ratio of 22.3X, as evidenced by the chart below. The overvaluation of the stock compared with its industry peers indicates its strong potential in the market, given the favorable trends backing it up.
Image Source: Zacks Investment Research
Notably, KBR and AECOM are currently trading at a forward 12-month P/E ratio of 11.78X and 20.72X, respectively.
Earnings Estimate Revision of EME
EME’s earnings estimates for 2025 and 2026 have remained unchanged over the past 60 days at $23.59 and $25.47 per share, respectively. However, the estimated figures for 2025 and 2026 imply year-over-year growth of 9.6% and 8%, respectively.
Image: Bigstock
Will Semiconductor and Biotech Drive EMCOR's Bookings?
Key Takeaways
EMCOR Group, Inc.’s (EME - Free Report) prospects are notably benefiting from several initiatives that the United States government has undertaken to foster public infrastructure. Initiatives like the CHIPS Act and the Inflation Reduction Act (IRA) are helping to fuel the demand across the semiconductor and biotech market segments, thus benefiting EMCOR in its wake.
As of March 31, 2025, EME reached a record value of $11.75 billion for remaining performance obligations (RPOs), including $1 billion of RPOs from Miller Electric. The value reflects 28% year-over-year growth. The company measures its to-be-realized revenues from received and incomplete contracts through remaining performance obligations or RPOs.
EME considers projects across semiconductors, biotech, life sciences and pharmaceuticals under the High-Tech Manufacturing market sector. During the first quarter of 2025, the company witnessed a setback in this sector’s RPOs, with continued progress across several multi-year semiconductor projects being one of the reasons behind it. However, from a long-term perspective, it is optimistic about increased spending in this market sector, especially across semiconductor, biotech and pharmaceuticals.
The market visibility for long-term prospects for semiconductor and biotech projects remains solid. It is because the market is currently focused on AI alternatives, technological revolution, and health and wellness. These trends, supported by several ongoing federal and state initiatives, are fueling the demand for such projects, thus boosting EMCOR’s booking visibility in the upcoming period. The company’s ability to grab onto these market opportunities and capitalize on them efficiently is boding well for its revenue visibility and margin trends.
EME Stock’s Price Performance vs Other Market Players
Shares of this Connecticut-based infrastructure service provider have gained 56.2% in the past three months, outperforming the Zacks Building Products - Heavy Construction industry, the broader Construction sector and the S&P 500 index. The detailed share price performance is shown in the chart below.
Image Source: Zacks Investment Research
Other renowned firms that share the market space with EME across semiconductors, biotech, life sciences and pharmaceuticals segments include KBR, Inc. (KBR - Free Report) and AECOM (ACM - Free Report) . Although the market trends are favoring these companies, they are falling behind in realizing benefits from the robust fundamentals compared with EMCOR. During the past three months, shares of KBR and AECOM have gained 3.1% and 32.6%, respectively.
EMCOR’s Valuation Trend
EMCOR stock is currently trading at a premium compared with the industry peers, with a forward 12-month price-to-earnings (P/E) ratio of 22.3X, as evidenced by the chart below. The overvaluation of the stock compared with its industry peers indicates its strong potential in the market, given the favorable trends backing it up.
Image Source: Zacks Investment Research
Notably, KBR and AECOM are currently trading at a forward 12-month P/E ratio of 11.78X and 20.72X, respectively.
Earnings Estimate Revision of EME
EME’s earnings estimates for 2025 and 2026 have remained unchanged over the past 60 days at $23.59 and $25.47 per share, respectively. However, the estimated figures for 2025 and 2026 imply year-over-year growth of 9.6% and 8%, respectively.
EPS Trend
Image Source: Zacks Investment Research
EME stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.